Enfortumab Vedotin–related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature

Enfortumab Vedotin–related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature

Enfortumab vedotin (EV) is an antibody-drug conjugate approved for the treatment of refractory advanced urothelial cancer. Cutaneous toxicity is well described but has not been correlated with response. In this retrospective single-center study, data from patients treated with more than one dose of...

Full description

Bibliographic Details
Main Authors: Evangelia Vlachou, Andres Matoso, David McConkey, Yuezhou Jing, Burles Avner Johnson, 3rd, Noah M. Hahn, Jean Hoffman-Censits
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:European Urology Open Science
Subjects:
Advanced urothelial cancer
African American
Bladder cancer
Cutaneous adverse events
Disease response
Enfortumab vedotin
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168323000022

Internet

http://www.sciencedirect.com/science/article/pii/S2666168323000022

Similar Items